{"id":36878,"date":"2015-09-21T07:24:14","date_gmt":"2015-09-21T11:24:14","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=36878"},"modified":"2015-09-21T07:24:14","modified_gmt":"2015-09-21T11:24:14","slug":"pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878","title":{"rendered":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR)"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Pharmacyte Biotech Inc (OTCMKTS:PMCB)<\/strong> <a href=\"https:\/\/finance.yahoo.com\/news\/pharmacyte-biotech-discusses-major-milestones-133000376.html\">announced<\/a> the list of major milestone tasks that it plans to achieve before it begins its Phase IIB trial in pancreatic cancer. The company stated it will have a clinical protocol that will be designed in coordination with Contract Research Organization and its team of oncologists. This designed protocol can be considered as a \u201crecipe\u201d on how the trials will be performed.<\/p>\n<p style=\"text-align: justify;\">The main factors that will be included in protocol are the qualifications required for particular patients to be enrolled in the study, the mode of use of Pharmacyte\u2019s treatment in the \u201ccomparator\u201d arm of the trial and the duration and schedule of these treatments, the specific \u201cendpoints\u201d for the clinical study and the data types that will be collected to assess these endpoints; and the types of data analysis to be used while conducting trial.<\/p>\n<p style=\"text-align: justify;\">In last trading session, the stock price of Pharmacyte jumped more than 3% to close the week at $0.0910.<\/p>\n<p style=\"text-align: justify;\"><strong>Natural Alternatives International, Inc. (NASDAQ:NAII) Files Complaint Against Creative Compounds Inc.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Natural Alternatives International, Inc. (NASDAQ:NAII)<\/strong> <a href=\"https:\/\/finance.yahoo.com\/news\/natural-alternatives-international-inc-files-193300528.html\">submitted<\/a> a Complaint against Creative Compounds Inc. to stop it from improperly and intentionally trying to mislead company&#8217;s potential and actual clients and wrongfully interfering with its CarnoSyn\u00ae beta-alanine business.<\/p>\n<p style=\"text-align: justify;\">Natural Alternatives offers beta-alanine to clients under the trademark CarnoSyn\u00ae and it owns a portfolio of 34 patents in the U.S. and foreign countries related to beta-alanine. In various scientific trials, CarnoSyn\u00ae beta-alanine, when utilized as a dietary supplement, has been validated to defer the fatigue onset in muscle cells, thus eliminating muscle soreness and fatigue. It has been demonstrated to enhance athletic performance.<\/p>\n<p style=\"text-align: justify;\">The company alleged that, on or near to September 5, Creative Compounds sent an internet communication to clients and potential clients of beta-alanine making various misleading and false statements pertaining to Creative&#8217;s generic beta-alanine, Natural Alternatives\u2019 CarnoSyn\u00ae beta-alanine, and its intellectual property rights.<\/p>\n<p style=\"text-align: justify;\"><strong>Uluru Inc (OTCMKTS:ULUR)<\/strong> posted strong session on Friday and jumped more than 38% to close the week at $0.388.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced the list of major milestone tasks that it plans to achieve before it begins its Phase IIB trial in pancreatic [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":32925,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[11754,11753,11752,11643,11679,11642,11641,11678,11677],"stock_ticker":[],"class_list":["post-36878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-nasdaqnaii","tag-natural-alternatives-international-inc","tag-natural-alternatives-international-inc-nasdaqnaii","tag-otcmktspmcb","tag-otcmktsulur","tag-pharmacyte-biotech-inc","tag-pharmacyte-biotech-inc-otcmktspmcb","tag-uluru-inc","tag-uluru-inc-otcmktsulur","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced the list of major milestone tasks that it plans to achieve before it begins its Phase IIB trial in pancreatic [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-09-21T11:24:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lisa Ray\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lisa Ray\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878\"},\"author\":{\"name\":\"Lisa Ray\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\"},\"headline\":\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR)\",\"datePublished\":\"2015-09-21T11:24:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg\",\"keywords\":[\"NASDAQ:NAII\",\"Natural Alternatives International Inc.\",\"Natural Alternatives International Inc. (NASDAQ:NAII)\",\"OTCMKTS:PMCB\",\"OTCMKTS:ULUR\",\"Pharmacyte Biotech Inc\",\"Pharmacyte Biotech Inc (OTCMKTS:PMCB)\",\"Uluru Inc\",\"Uluru Inc (OTCMKTS:ULUR)\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878\",\"name\":\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg\",\"datePublished\":\"2015-09-21T11:24:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\",\"name\":\"Lisa Ray\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"caption\":\"Lisa Ray\"},\"description\":\"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878","og_locale":"en_US","og_type":"article","og_title":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR) - Wall Street PR","og_description":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced the list of major milestone tasks that it plans to achieve before it begins its Phase IIB trial in pancreatic [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-09-21T11:24:14+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg","type":"image\/jpeg"}],"author":"Lisa Ray","twitter_misc":{"Written by":"Lisa Ray","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878"},"author":{"name":"Lisa Ray","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c"},"headline":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR)","datePublished":"2015-09-21T11:24:14+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg","keywords":["NASDAQ:NAII","Natural Alternatives International Inc.","Natural Alternatives International Inc. (NASDAQ:NAII)","OTCMKTS:PMCB","OTCMKTS:ULUR","Pharmacyte Biotech Inc","Pharmacyte Biotech Inc (OTCMKTS:PMCB)","Uluru Inc","Uluru Inc (OTCMKTS:ULUR)"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878","url":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878","name":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg","datePublished":"2015-09-21T11:24:14+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/biotech.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-to-design-clinical-protocol-naii-ulur-36878#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Design Clinical Protocol (NAII, ULUR)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c","name":"Lisa Ray","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","caption":"Lisa Ray"},"description":"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=36878"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36878\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/32925"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=36878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=36878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=36878"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=36878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}